RAD51 and breast cancer: Beyond validating miR-222 overexpression in tamoxifen resistant cells, this is the first demonstration that upregulation of miR-222 increases PARP1 activation and PARPi sensitivity and decreases RAD51 foci formation in breast cancer cells.